Sign in Subscribe

article

A collection of 632 issues

Study evaluates potential hearing damage from oxaliplatin in preclinical model

Skip to content The CRC Digest ♥ LIVING WITH CRC Study evaluates potential hearing damage from oxaliplatin in preclinical model Mouse study evaluated potential hearing damage induced by oxaliplatin. (Hearing Research) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The

NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis

Skip to content The CRC Digest ◇ RESEARCH NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis Preclinical research found that the NF-κB/LCN2 signaling pathway enhances cisplatin sensitivity in BRAF V600E-mutant CRC cells through iron-dependent cell death. (Cancers) This content is informational only and does

Immunotherapy produces durable responses in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status

Skip to content The CRC Digest ▸ TREATMENT Immunotherapy produces durable responses in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status Patients with dMMR/MSI-H tumors who had poor performance status still achieved durable responses to immunotherapy, expanding treatment options for this vulnerable group. (Clinical Colorectal Cancer) This content

Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer The prospective, randomized FIND trial used dynamic ctDNA methylation monitoring to personalize follow-up care after surgery in stage I-III patients. (Journal of Clinical Oncology) This

Genomic Differences Between Early-Onset and Average-Onset Metastatic CRC Identified

Skip to content The CRC Digest ◇ RESEARCH Genomic Differences Between Early-Onset and Average-Onset Metastatic CRC Identified A real-world next-generation sequencing study compared the genomic landscape of early-onset colorectal cancer with average-onset metastatic disease, identifying distinct molecular features in younger patients. (JCO Precision Oncology) This content is informational only and does

Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC A phase 1b/2 trial found that ifebemtinib plus garsorasib demonstrated anticancer activity and manageable safety in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer, though the improvement in response rate did not

Whole-Genome Electrical Impedance Assay Detects DNA Hypomethylation for CRC Screening

Skip to content The CRC Digest ▪ SCREENING Whole-Genome Electrical Impedance Assay Detects DNA Hypomethylation for CRC Screening A rapid, label-free cell-free DNA assay measures global DNA hypomethylation—a hallmark of colorectal cancer—using electrical impedance to differentiate healthy individuals from those with cancer in a retrospective validation study. (Computational and

Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer The multicenter phase III TNTCRT trial compared total neoadjuvant therapy using long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology) This content is informational

Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC The DEEPER trial presents final analysis of long-term survival outcomes comparing modified-FOLFOXIRI plus cetuximab versus bevacizumab in patients with RAS and BRAF wild-type metastatic colorectal cancer. (Journal of Clinical Oncology) This

COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC The COMMIT trial is a randomized study comparing atezolizumab alone versus mFOLFOX6/bevacizumab/atezolizumab as first-line treatment of deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology) This content